Anesthesiology and Intensive Care Department, University Hospital of La Guadeloupe, F-97139 Les Abymes, France.
Université Paris Cité and Université des Antilles, INSERM, BIGR, F-75015 Paris, France.
Medicina (Kaunas). 2023 Dec 18;59(12):2196. doi: 10.3390/medicina59122196.
: Pain management poses a significant challenge for patients experiencing vaso-occlusive crisis (VOC) in sickle cell disease (SCD). While opioid therapy is highly effective, its efficacy can be impeded by undesirable side effects. Local regional anesthesia (LRA), involving the deposition of a perineural anesthetic, provides a nociceptive blockade, local vasodilation and reduces the inflammatory response. However, the effectiveness of this therapeutic approach for VOC in SCD patients has been rarely reported up to now. The objective of this study was to assess the effectiveness of a single-shot local regional anesthesia (LRA) in reducing pain and consequently enhancing the management of severe vaso-occlusive crisis (VOC) in adults with sickle cell disease (SCD) unresponsive to conventional analgesic therapy. : We first collected consecutive episodes of VOC in critical care (ICU and emergency room) for six months in 2022 in a French University hospital with a large population of sickle cell patients in the West Indies population. We also performed a systematic review of the use of LRA in SCD. The primary outcome was defined using a numeric pain score (NPS) and/or percentage of change in opioid use. : We enrolled nine SCD adults (28 years old, 4 females) for ten episodes of VOC in whom LRA was used for pain management. Opioid reduction within the first 24 h post block was -75% (50 to 96%). Similarly, the NPS decreased from 9/10 pre-block to 0-1/10 post-block. Five studies, including one case series with three patients and four case reports, employed peripheral nerve blocks for regional anesthesia. In general, local regional anesthesia (LRA) exhibited a reduction in pain and symptoms, along with a decrease in opioid consumption post-procedure. : LRA improves pain scores, reduces opioid consumption in SCD patients with refractory pain, and may mitigate opioid-related side effects while facilitating the transition to oral analgesics. Furthermore, LRA is a safe and effective procedure.
: 疼痛管理对于镰状细胞病 (SCD) 患者经历血管阻塞性危象 (VOC) 是一项重大挑战。尽管阿片类药物治疗非常有效,但它的疗效可能会受到不良副作用的影响。局部区域麻醉 (LRA) 涉及神经周围麻醉剂的沉积,可提供疼痛阻断、局部血管扩张并减少炎症反应。然而,到目前为止,这种治疗方法对 SCD 患者 VOC 的有效性很少有报道。本研究的目的是评估单次局部区域麻醉 (LRA) 在减轻疼痛方面的有效性,从而增强对镰状细胞病 (SCD) 成人严重血管阻塞性危象 (VOC) 的管理,这些患者对常规镇痛治疗无反应。 : 我们首先在 2022 年的一家法国大学医院的重症监护病房 (ICU 和急诊室) 连续收集了六个月的 VOC 发作,该医院有大量西印度群岛的镰状细胞患者。我们还对 LRA 在 SCD 中的应用进行了系统评价。主要结果使用数字疼痛评分 (NPS) 和/或阿片类药物使用变化百分比来定义。 : 我们纳入了 9 名 SCD 成人 (28 岁,女性 4 名),共 10 例 VOC 发作,使用 LRA 进行疼痛管理。阻滞后 24 小时内阿片类药物的减少量为 -75%(50%至 96%)。同样,NPS 从阻滞前的 9/10 降至阻滞后的 0-1/10。五项研究,包括一项有 3 名患者的病例系列研究和四项病例报告,采用外周神经阻滞进行区域麻醉。一般来说,局部区域麻醉 (LRA) 可减轻疼痛和症状,并减少术后阿片类药物的使用。 : LRA 可改善疼痛评分,减少 SCD 患者难治性疼痛中的阿片类药物消耗,并可能减轻阿片类药物相关副作用,同时促进向口服镇痛剂过渡。此外,LRA 是一种安全有效的程序。